SCHEMBL2323855

SCHEMBL2323855

Cc1cc(C)c(-c2ccc(C=O)o2)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.44
▸ KDM4E B2RXH2 8/20 0.44
▸ LMNA P02545 2/20 0.44
▸ ALOX5 P09917 1/20 0.43
▸ POLB P06746 5/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.41
▸ MAPT P10636 5/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ CYP2E1 P05181 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2B6 P20813 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3039493 0.83 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL2321869 0.79 KDM4E (0.47) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL6656195 0.75 ALDH1A1 (0.61) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL2318474 0.73 KDM4E (0.67) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL5737282 0.73 KDM4E (0.56) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL8412536 0.73 ALDH1A1 (0.59) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL2324212 0.71 ALDH1A1 (0.60) ALDH1A1KDM4ELMNAALOX5POLB
SCHEMBL2323850 0.70 ALOX5 (0.43) ALOX5
SCHEMBL2321506 0.70 KDM4E (0.58) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2
SCHEMBL1116271 0.70 BRD4 (0.53) ALDH1A1KDM4ELMNAPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338465-B2 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis CORNELL RESEARCH FOUNDATION, INC. (US) 2012-12-25 — — US disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 — — WO disclosed
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS CORNELL RESEARCH FOUNDATION, INC. 2010-08-19 — — US disclosed
WO-2008005651-A2 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS DECODE CHEMISTRY, INC. (US) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS RARG, SDHA, RARS2 ALDH1A1 270/4885KDM4E 4138/4885LMNA 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback